BG Medicine Welcomes CE Mark for Galectin-3 Test

BG Medicine Welcomes CE Mark for Galectin-3 Test

WALTHAM, Mass., April 10, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc.
(Nasdaq:BGMD), a company focused on the development and commercialization of
novel cardiovascular diagnostics, welcomed the announcement today that Abbott
has obtained a CE Mark for the Galectin-3 assay run on the ARCHITECT
immunochemistry platform.

The launch of the ARCHITECT Galectin-3 test under CE Mark will further expand
the availability of galectin-3 testing in several European countries, pending
country registration. BG Medicine is partnering with four diagnostic
instrument manufacturers to commercialize automated versions of the BGM
Galectin-3 test.

"The launch of the ARCHITECT Galectin-3 test under CE Mark is another
important step in our commercial strategy. We are very pleased with the
progress made by our partner Abbott, a worldwide leader in in vitro
diagnostics, to expand the use of galectin-3 testing in heart failure
patients," said Eric Bouvier, President and Chief Executive Officer of BG
Medicine. The announcement will strengthen our ability to drive the growth of
galectin-3 testing throughout the world."

"Galectin-3 is a powerful indicator of prognosis and risk for readmission in
heart failure. Having a rapid turn-around galectin-3 result means heart
failure patients at high-risk for such adverse events can be more readily
identified," said Stefan Anker MD, PhD and President of the Heart Failure
Association of the European Society of Cardiology. "Given the rise in heart
failure, it is critical we introduce new tools that aid fast clinical decision
making processes and provide options to explore new interventions."

In addition to Abbott, BG Medicine is partnering with Alere Inc., bioMérieux
SA, and Siemens Healthcare Diagnostics Inc. to supply automated versions of
its galectin-3 test to key segments of the market. Earlier this year,
bioMérieux SA launched the test in Europe and in certain other territories
that recognize the CE Mark.

About Galectin-3 testing

Galectin-3 has been implicated in a variety of biological processes important
in the development and progression of heart failure. Higher levels of
galectin-3 are associated with a more aggressive form of heart failure, which
may make identification of high-risk patients using galectin-3 testing an
important part of patient care. Galectin-3 testing may be useful in helping
physicians determine which patients are at higher risk of death or
hospitalization, including 30-day readmission.

About BG Medicine, Inc.

BG Medicine, Inc. (Nasdaq:BGMD) is a diagnostics company focused on the
development and commercialization of novel cardiovascular tests to address
significant unmet medical needs, improve patient outcomes and reduce
healthcare costs. The Company has two products: the BGM Galectin-3^® test for
use in patients with chronic heart failure is available in the United States
and Europe; and the CardioSCORE™ test for the risk prediction of major
cardiovascular events is expected to be launched in Europe in the first half
of 2013. For additional information about BG Medicine, heart failure and
galectin-3 testing, please visit www.bg-medicine.com and www.galectin-3.com.

The BG Medicine Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=10352

Forward-Looking Statements

Certain statements made in this news release contain forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities and Exchange Act of 1934, as
amended, that are intended to be covered by the "safe harbor" created by those
sections. Forward-looking statements, which are based on certain assumptions
and describe our future plans, strategies and expectations, can generally be
identified by the use of forward-looking terms such as "believe," "expect,"
"may," "will," "should," "could," "seek," "intend," "plan," "estimate,"
"anticipate" or other comparable terms. Forward-looking statements in this
news release address our belief that the launch of the ARCHITECT Galectin-3
test under CE Mark will further expand the availability of galectin-3 testing
in several European countries and our belief regarding the importance of the
launch in our commercial strategy; our understanding that higher levels of
galectin-3 are associated with a more aggressive form of heart failure, which
may make identification of high-risk patients using galectin-3 testing an
important part of patient care; and our belief that galectin-3 testing may be
useful in helping physicians determine which patients are at high risk of
cardiovascular death or hospitalization, including 30-day readmission.
Forward-looking statements are based on management's current expectations and
involve inherent risks and uncertainties which could cause actual results to
differ materially from those in the forward-looking statements, as a result of
various factors including those risks and uncertainties described in the Risk
Factors and in Management's Discussion and Analysis of Financial Condition and
Results of Operations sections of our recent filings with the Securities and
Exchange Commission, including our most recent Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q. We urge you to consider those risks and
uncertainties in evaluating our forward-looking statements. We caution readers
not to place undue reliance upon any such forward-looking statements, which
speak only as of the date made. Except as otherwise required by the federal
securities laws, we disclaim any obligation or undertaking to publicly release
any updates or revisions to any forward-looking statement contained herein (or
elsewhere) to reflect any change in our expectations with regard thereto or
any change in events, conditions or circumstances on which any such statement
is based.

CONTACT: Chuck Abdalian
         EVP & Chief Financial Officer
         (781) 434-0210

BG Medicine Inc. logo